Shares of precision cardiovascular product company Cardio Diagnostics (NASDAQ:CDIO) are in the focus today after it launched the first integrated epigenetic-genetic-based blood test, PrecisionCHD, for detecting coronary heart disease.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
This is the second test launched for this indication by CDIO and it also plans to bring to market a series of tests for other cardiovascular diseases and conditions over the next two years.
In the U.S., about 800,000 people experience a heart attack every year. Next, the test will be initially available for the company’s existing customers followed by a country-wide rollout.
Shares of the company have already zoomed up 216.5% over the past month alone.
Read full Disclosure
